Poseida Therapeutics, Inc. (PSTX) Bundle
A Brief History of Poseida Therapeutics, Inc. (PSTX)
Company Overview
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company focuses on developing cell and gene therapies for cancer and other challenging diseases.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $163.52 million |
| Total Revenue | $11.4 million |
| Net Loss | $96.3 million |
| Cash and Cash Equivalents | $86.2 million |
Key Pipeline Programs
- P-BCMA-101: Multiple myeloma CAR-T therapy
- P-MUC1C-101: Solid tumor immunotherapy
- P-HSC-GDXT: Genetic disorder gene therapy
Clinical Trial Status
As of 2024, Poseida has multiple ongoing clinical trials in Phase 1/2 stages across various therapeutic areas.
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| NASDAQ Ticker | PSTX |
| Current Stock Price | $1.87 |
| 52-Week Range | $1.05 - $4.25 |
Research and Development
Poseida invested $106.7 million in research and development expenses in 2023.
Who Owns Poseida Therapeutics, Inc. (PSTX)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc. | 2,214,440 | 9.22% |
| BlackRock Inc. | 1,893,405 | 7.88% |
| Orbimed Advisors LLC | 1,521,221 | 6.33% |
Insider Ownership
As of the latest filing, key insider ownership includes:
- Eric Ostertag - Chairman and CEO: 1,245,678 shares
- Mark Gergen - Chief Financial Officer: 345,221 shares
- Matthew Loar - Chief Operating Officer: 278,543 shares
Top Institutional Investors
| Investor | Total Value of Holdings | Reporting Date |
|---|---|---|
| Fidelity Management & Research | $14,523,000 | Q4 2023 |
| Goldman Sachs Group Inc. | $9,876,000 | Q4 2023 |
| Morgan Stanley | $7,654,000 | Q4 2023 |
Ownership Breakdown
Total Outstanding Shares: 24,023,456
- Institutional Investors: 68.5%
- Insider Ownership: 12.3%
- Retail Investors: 19.2%
Poseida Therapeutics, Inc. (PSTX) Mission Statement
Company Overview
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative cell and gene therapies for patients with serious diseases.
Financial Performance
| Metric | Value | Period |
|---|---|---|
| Market Capitalization | $183.42 million | Q4 2023 |
| Cash and Cash Equivalents | $126.7 million | September 30, 2023 |
| Net Loss | $41.3 million | Q3 2023 |
Research and Development Focus
- Gene editing technologies
- CAR-T cell therapies
- Allogeneic cell therapies
Key Therapeutic Areas
Primary therapeutic targets include:
- Hematologic malignancies
- Solid tumors
- Genetic disorders
Clinical Pipeline
| Program | Indication | Clinical Stage |
|---|---|---|
| P-BCMA-ALLO1 | Multiple Myeloma | Phase 1/2 |
| P-MUC1C-ALLO1 | Solid Tumors | Phase 1 |
Technological Platforms
- NextCure Transgene Insertion (nTi) Platform
- Determinant Targeting (DT) Platform
Corporate Information
Headquarters: San Diego, California
Founded: 2014
NASDAQ Ticker: PSTX
How Poseida Therapeutics, Inc. (PSTX) Works
Company Overview
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative cell and gene therapies for challenging diseases.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $14.3 million |
| Net Loss | $119.6 million |
| Cash and Cash Equivalents | $134.7 million |
Key Technology Platforms
- NextCar™ CAR-T Platform
- P-BCMA-101 CAR-T therapy for multiple myeloma
- P-MUC1C-101 CAR-T therapy for solid tumors
Clinical Pipeline
Poseida focuses on developing therapies in the following therapeutic areas:
- Multiple Myeloma
- Solid Tumors
- Hematologic Malignancies
Research and Development Expenses
| Year | R&D Expenses |
|---|---|
| 2022 | $95.4 million |
| 2023 | $106.2 million |
Stock Information
As of January 2024:
- Stock Symbol: PSTX
- Average Trading Volume: 441,000 shares
- Market Capitalization: Approximately $180 million
How Poseida Therapeutics, Inc. (PSTX) Makes Money
Revenue Streams
Poseida Therapeutics, Inc. generates revenue primarily through research and development funding, grants, and potential future licensing or collaboration agreements for its cell therapy platforms.
| Revenue Source | Amount (2023) |
|---|---|
| Research Grants | $12.3 million |
| Collaboration Revenue | $4.7 million |
| Total Revenue | $17.0 million |
Research and Development Focus
Poseida concentrates on developing cell therapies for cancer and other challenging diseases.
- Gene editing technologies
- CAR-T cell therapies
- Allogeneic cell therapy platforms
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Net Loss | $129.4 million |
| Research and Development Expenses | $94.2 million |
| Cash and Cash Equivalents | $191.6 million |
Funding Sources
- Public equity offerings
- Private placements
- Research grants
- Potential milestone payments from partnerships
Poseida Therapeutics, Inc. (PSTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.